UniQure stock pops following FDA’s reversal allowing Huntington’s disease therapy AMT-130 to move toward US approval filing.
The article explicitly reports that UniQure shares surged after the FDA reversed its stance on the company’s Huntington’s disease gene therapy, allowing a US filing. This regulatory green light removes a key uncertainty and paves the way for potential approval, directly boosting the stock.
The FDA reversal signals a higher likelihood of AMT-130 reaching the US market, which could generate significant revenue for UniQure. The stock’s rally reflects increased probability of upside from the Huntington’s disease therapy.
The surge prices in some of the positive news, but further upside depends on the FDA’s review process and eventual approval. Investors should monitor upcoming filings and any additional FDA feedback.
While the news is specific to UniQure, it may be seen as a positive signal for gene therapy developers facing regulatory challenges, though direct impact on competitors is limited.
UniQure shares surged after the FDA reversed course on its Huntington’s disease gene therapy, allowing the company to file for US approval. The regulatory pivot removes a key overhang and accelerates the path to market for the treatment. Investors bid up the stock on the prospect of a new revenue stream.
The FDA reversed its previous decision and will now allow UniQure to submit a biologics license application (BLA) for its gene therapy AMT-130, designed to treat Huntington’s disease.
The reversal removes a major regulatory roadblock that had stalled the therapy’s US market entry, potentially accelerating the timeline to approval and revenue generation.
UniQure shares soared, with the stock price jumping sharply in trading, reflecting investor relief and optimism about the therapy’s prospects.